Damora Therapeutics, Inc. (DMRA)
30.62
+0.31
(+1.02%)
USD |
NASDAQ |
Aug 25, 16:00
30.74
+0.12
(+0.39%)
After-Hours: 19:59
Damora Therapeutics Shareholders Equity (Quarterly) : 516.06M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 516.06M |
| March 31, 2026 | 510.26M |
| December 31, 2025 | 239.04M |
| September 30, 2025 | 6.666M |
| June 30, 2025 | 9.612M |
| March 31, 2025 | 12.35M |
| December 31, 2024 | 14.47M |
| September 30, 2024 | 20.94M |
| June 30, 2024 | 23.59M |
| March 31, 2024 | 28.16M |
| December 31, 2023 | 32.33M |
| September 30, 2023 | 37.38M |
| Date | Value |
|---|---|
| June 30, 2023 | 43.70M |
| March 31, 2023 | 50.33M |
| December 31, 2022 | 61.75M |
| September 30, 2022 | 72.73M |
| June 30, 2022 | 85.06M |
| March 31, 2022 | 101.31M |
| December 31, 2021 | 117.22M |
| September 30, 2021 | 129.62M |
| June 30, 2021 | 141.43M |
| March 31, 2021 | 152.57M |
| December 31, 2020 | 165.49M |
| September 30, 2020 | 89.28M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 543.64M |
| Total Liabilities (Quarterly) | 27.58M |
| Current Ratio | 19.73 |
| Net Debt Paydown Yield | 0.02% |